BLSM
BlossomHill Therapeutics, Inc.
Price Chart
Latest Quote
$15.84
-0.55 (-3.34%)
Current Price
| Previous Close | $16.39 |
| Open | $16.34 |
| Day High | $16.94 |
| Day Low | $15.84 |
| Volume | 35,866 |
Stock Information
| Shares Outstanding | 31.78M |
| Total Debt | $23.37M |
| Cash Equivalents | $95.38M |
| Net Income | $-81.60M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $503.55M |
| EPS (TTM) | $-4.70 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $705.77M |
| Income | $-81.60M |
| Book/sh | $-63.15 |
| Cash/sh | $3.00 |
| Employees | 69 |
Financial Ratios
| Quick Ratio | 5.12 |
| Current Ratio | 5.42 |
| Debt/Eq | 28.49 |
Returns & Margins
Ownership
| Insider Ownership | 12.71% |
| Institutional Ownership | 31.88% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.01 |
| P/B | -0.25 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $35.40 |
Technical Indicators
| SMA20 | $16.44 |
| SMA50 | $19.03 |
| RSI | 46.07 |
| ATR | 1.3712 |
| Shares Float | 17.74M |
| Short Ratio | 2.11 |
| Rel Volume | 0.22 |
Performance History
| Week | +10.02% |
| Month | -25.76% |
| YTD | -0.98% |
| 10 Years | -0.98% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $15.84 | 35,866 |
| 2026-10-26 | $16.39 | 204,400 |
| 2026-10-23 | $14.63 | 84,300 |
| 2026-10-22 | $15.81 | 98,000 |
| 2026-10-21 | $15.60 | 76,200 |
| 2026-10-20 | $14.40 | 74,900 |
| 2026-10-19 | $14.16 | 189,400 |
| 2026-10-16 | $13.94 | 293,100 |
| 2026-10-15 | $14.98 | 176,500 |
| 2026-10-14 | $15.26 | 170,200 |
| 2026-10-13 | $15.48 | 118,600 |
| 2026-10-12 | $17.27 | 91,100 |
| 2026-10-09 | $17.48 | 131,800 |
| 2026-10-08 | $16.88 | 165,200 |
| 2026-10-07 | $16.61 | 253,800 |
| 2026-10-06 | $17.29 | 247,400 |
| 2026-10-05 | $19.94 | 201,500 |
| 2026-10-02 | $19.69 | 169,300 |
| 2026-10-01 | $18.59 | 152,600 |
| 2026-09-30 | $18.64 | 362,200 |
| 2026-09-29 | $21.37 | 228,500 |
| 2026-09-28 | $21.34 | 146,400 |
About BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on BLSM.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Total Expenses | $64,024,000 | $36,401,000 |
| Other Income Expense | $-11,000 | - |
| Other Non Operating Income Expenses | $-11,000 | - |
| Net Non Operating Interest Income Expense | $3,480,000 | $5,706,000 |
| Operating Expense | $64,024,000 | $36,401,000 |
| General And Administrative Expense | $7,886,000 | $4,591,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-60,555,000 | $-30,695,000 |
| Net Interest Income | $3,480,000 | $5,706,000 |
| Interest Income | $3,480,000 | $5,706,000 |
| Normalized Income | $-60,555,000 | $-30,695,000 |
| Net Income From Continuing And Discontinued Operation | $-60,555,000 | $-30,695,000 |
| Total Operating Income As Reported | $-64,024,000 | $-36,401,000 |
| Net Income Common Stockholders | $-60,555,000 | $-30,695,000 |
| Net Income | $-60,555,000 | $-30,695,000 |
| Net Income Including Noncontrolling Interests | $-60,555,000 | $-30,695,000 |
| Net Income Continuous Operations | $-60,555,000 | $-30,695,000 |
| Pretax Income | $-60,555,000 | $-30,695,000 |
| Interest Income Non Operating | $3,480,000 | $5,706,000 |
| Operating Income | $-64,024,000 | $-36,401,000 |
| Per Share | ||
| Diluted EPS | $-3.69 | $-1.47 |
| Basic EPS | $-3.69 | $-1.47 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-63,583,000 | $-36,051,000 |
| Reconciled Depreciation | $441,000 | $350,000 |
| EBITDA (Bullshit earnings) | $-63,583,000 | $-36,051,000 |
| EBIT | $-64,024,000 | $-36,401,000 |
| Diluted Average Shares | $16,405,139 | $30,643,660 |
| Basic Average Shares | $16,405,139 | $20,839,066 |
| Diluted NI Availto Com Stockholders | $-60,555,000 | $-30,695,000 |
| Research And Development | $56,138,000 | $31,810,000 |
| Selling General And Administration | $7,886,000 | $4,591,000 |
| Other Gand A | $7,886,000 | $4,591,000 |
Fetched: 2026-10-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-131,817,000 | $-72,972,000 |
| Total Assets | $162,968,000 | $106,775,000 |
| Total Non Current Assets | $24,142,000 | $2,603,000 |
| Other Non Current Assets | $2,495,000 | $1,017,000 |
| Goodwill And Other Intangible Assets | $89,000 | $89,000 |
| Other Intangible Assets | $89,000 | $89,000 |
| Current Assets | $138,826,000 | $104,172,000 |
| Other Current Assets | $2,144,000 | $4,025,000 |
| Cash Cash Equivalents And Short Term Investments | $136,682,000 | $100,147,000 |
| Cash And Cash Equivalents | $136,682,000 | $100,147,000 |
| Debt | ||
| Total Debt | $22,398,000 | $525,000 |
| Long Term Debt And Capital Lease Obligation | $22,393,000 | $0 |
| Current Debt And Capital Lease Obligation | $5,000 | $525,000 |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $294,696,000 | $179,658,000 |
| Total Non Current Liabilities Net Minority Interest | $279,216,000 | $172,885,000 |
| Current Liabilities | $15,480,000 | $6,773,000 |
| Payables And Accrued Expenses | $15,475,000 | $6,248,000 |
| Payables | $2,314,000 | $849,000 |
| Accounts Payable | $2,314,000 | $849,000 |
| Equity | ||
| Common Stock Equity | $-131,728,000 | $-72,883,000 |
| Total Equity Gross Minority Interest | $-131,728,000 | $-72,883,000 |
| Stockholders Equity | $-131,728,000 | $-72,883,000 |
| Retained Earnings | $-135,029,000 | $-74,474,000 |
| Preferred Securities Outside Stock Equity | $256,823,000 | $172,885,000 |
| Other | ||
| Ordinary Shares Number | $30,643,660 | $30,643,660 |
| Share Issued | $30,643,660 | $30,643,660 |
| Tangible Book Value | $-131,817,000 | $-72,972,000 |
| Invested Capital | $-131,728,000 | $-72,883,000 |
| Working Capital | $123,346,000 | $97,399,000 |
| Capital Lease Obligations | $22,398,000 | $525,000 |
| Total Capitalization | $-131,728,000 | $-72,883,000 |
| Additional Paid In Capital | $3,300,000 | $1,590,000 |
| Capital Stock | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 |
| Long Term Capital Lease Obligation | $22,393,000 | $0 |
| Current Capital Lease Obligation | $5,000 | $525,000 |
| Current Accrued Expenses | $13,161,000 | $5,399,000 |
| Net PPE | $21,558,000 | $1,497,000 |
| Accumulated Depreciation | $-1,251,000 | $-959,000 |
| Gross PPE | $22,809,000 | $2,456,000 |
| Leases | $268,000 | $103,000 |
| Other Properties | $21,501,000 | $2,049,000 |
| Machinery Furniture Equipment | $1,040,000 | $304,000 |
| Properties | $0 | $0 |
Fetched: 2026-10-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-47,992,000 | $-31,508,000 |
| Operating Activities | ||
| Operating Cash Flow | $-46,925,000 | $-31,416,000 |
| Cash Flow From Continuing Operating Activities | $-46,925,000 | $-31,416,000 |
| Investing Activities | ||
| Capital Expenditure | $-1,067,000 | $-92,000 |
| Investing Cash Flow | $-1,067,000 | $-92,000 |
| Cash Flow From Continuing Investing Activities | $-1,067,000 | $-92,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $83,938,000 | $17,140,000 |
| Financing Cash Flow | $84,527,000 | $17,560,000 |
| Cash Flow From Continuing Financing Activities | $84,527,000 | $17,560,000 |
| Net Preferred Stock Issuance | $83,938,000 | $17,140,000 |
| Preferred Stock Issuance | $83,938,000 | $17,140,000 |
| Other | ||
| End Cash Position | $136,682,000 | $100,147,000 |
| Beginning Cash Position | $100,147,000 | $114,095,000 |
| Changes In Cash | $36,535,000 | $-13,948,000 |
| Proceeds From Stock Option Exercised | $589,000 | $420,000 |
| Net PPE Purchase And Sale | $-1,067,000 | $-92,000 |
| Purchase Of PPE | $-1,067,000 | $-92,000 |
| Change In Working Capital | $10,811,000 | $-2,272,000 |
| Change In Other Current Liabilities | $1,150,000 | $-725,000 |
| Change In Other Current Assets | $-1,478,000 | $931,000 |
| Change In Payables And Accrued Expense | $9,227,000 | $2,069,000 |
| Change In Accrued Expense | $7,762,000 | $3,207,000 |
| Change In Payable | $1,465,000 | $-1,138,000 |
| Change In Account Payable | $1,465,000 | $-1,138,000 |
| Change In Prepaid Assets | $1,912,000 | $-4,547,000 |
| Other Non Cash Items | $1,288,000 | $697,000 |
| Stock Based Compensation | $1,090,000 | $504,000 |
| Depreciation Amortization Depletion | $441,000 | $350,000 |
| Depreciation And Amortization | $441,000 | $350,000 |
| Depreciation | $441,000 | $350,000 |
| Net Income From Continuing Operations | $-60,555,000 | $-30,695,000 |
Fetched: 2026-08-11